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Abstract 
A full-length cDNA encoding a novel cytosolic protein-tyrosine phosphatase (PTP), PTP-BAS, was cloned from human basophils. Due to in-frame 
deletions in the coding region, PTP-BAS exists in three isoforms: 7,455 bp (2,485 aa) for type 1, 7,398 bp (2,466 aa) for type 2 and 6,882 bp (2,294 
aa) for type 3. All three isoforms contain a single PTP catalytic domain at the carboxyl termini as well as two distinct structural sequences. Amino 
terminal sequences of 300 amino acids are homologous to membrane-binding domains of cytoskeleton-associated proteins. Three 90 amino acid 
internal repetitive sequences are homologous to the GLGF repeats found in guanylate kinase proteins. PTP-BAS was expressed in various human 
tissues, especially highly in the kidney and lung. Interestingly, the BAS mRNA level in the fetal brain was remarkably high. 
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Introduction 
The cross-linking of high affinity IgE receptors 
(FcsRI) on basophils and mast cells leads to the immedi- 
ate release of allergic mediators. Studies using murine 
cell lines have demonstrated that FcERI-mediated tyro- 
sine phosphorylation is a major initial signal transducer. 
Protein-tyrosine kinases (PTKs) of the Src family (Lyn, 
c-Src and c-Yes [l]) and PTK72 [2] associate with the 
receptor and become activated after FcERI cross-linking, 
leading to tyrosine phosphorylation of multiple proteins. 
Such enhanced phosphorylation is diminished immedi- 
ately when cross-linking is reversed [3,4]. Thus, dephos- 
phorylation by protein-tyrosine phosphatases (PTPs) 
has also been considered to be important in initial signal 
transduction via Fc&RI [5], but this has not been investi- 
gated in detail [6,7]. Human basophils and mast cells 
have not been studied widely, because they are difficult 
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to obtain and human cell lines have not yet been estab- 
lished. 
We have been able to cultivate and differentiate 
human basophils [8]. In the present study, we isolated 
them using a fluorescence-activated cell sorter (FACS). 
PTPs expressed in the isolated basophils were identified 
by polymerase chain reaction (PCR) using degenerative 
primers. A novel PTP (named PTP-BAS) was found. Its 
full-length cDNA was cloned, sequenced and character- 
ized. 
2. Materials and methods 
2.1. Reagents 
Fluorescein amidite (FluorePrime), the mRNA purification Kit, the 
QuickPrep Micro mRNA Purification Kit and the Ready-To-Go-DNA 
Labeling Kit were obtained from Pharmacia. The pCR II vector was 
from a TA Cloning Kit (Invitrogen). The SUPERSCRIPT Lambda 
System, SUPERSCRIPT Reverse Transcriptase, 5’ RACE System and 
dsDNA Cycle Sequencing System were purchased from GIBCO BRL. 
Oligo(dT)lS was from Boehringer Mannheim. The lZAP IIIEcoRI 
Cloning Kit and Gigapack II Gold packaging extract were obtained 
from Stratagene. Multiple Tissue Northern Blots and a human G3PDH 
control probe were provided by CLONTECH. 
2.2. Basophil-enriched cell culture 
KU812E, a subclone of the human chronic myelogeneous leukemic 
cell line, KU812, was obtained from the Japanese Cancer Research 
Resources Bank (JCRB 0104.1), and maintained in RPM1 1640 me- 
dium supplemented with 10% fetal calf serum. To facilitate the growth 
and differentiation of basophils, the cells were cultured in the serum- 
free medium, COSMEDIUM-003 (COSMO-BIO), supplemented with 
200 units/ml of recombinant human IL-3 (Genzyme) for 2-3 weeks [8]. 
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2.3. FACS sorting of basophils 
Basophil-enriched cells were stained successively with human IgE, 
F(ab’)Z fragment of mouse anti-human IgE monoclonal antibody and 
FITC-conjugated anti-mouse IgG. After further staining with propid- 
ium iodide, the cells were analyzed on a FACStarrLUS flow cytometer 
(Becton Dickinson). Fluorescence was measured at 530 (FLl) and 630 
nm (FL2) for FITC and propidium iodide, respectively. Basophils ex- 
clusively expressing high-affinity IgE receptors in the culture cells, were 
sorted as the FL1 positive/FL2 negative fraction by FL1 and FL2 
gating. 
2.4. Oligonucleotide synthesis 
Oligonucleotides were synthesized using a DNA synthesizer (CY- 
CLONE, MilliGen). 5’-Fluorescein-labelled oligonucleotides were syn- 
thesized as above by means of fluorescein amidite and used as the 
primer for sequencing on an ALF DNA sequencer (Pharmacia). A pair 
of degenerate oligonucleotides, A and B, were designed from two highly 
conserved amino acid sequences within the PTP catalytic domain [9]. 
Oligonucleotides A (sense) and B (antisense) were based on the respec- 
tive sequences of FWRM (I or V) W (E or Q) [S-TT(C/ 
T)TGGCGIATG(G/A)TITGG(C/G)A_3’l and HCSAG (V or I) G [S- 
CC(G/A)A(C/T)ICCNGCIGA(A/G)CA(A/G)TG-31, where I is inos- 
ine and N is a mixture of A, C, G and T in oligonucleotide sequences. 
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2.5. PCR 
2.5.1. Amplification of the PTP catalytic domain 
Polv(A)’ RNA was isolated from 1.6 x lo6 FACS-sorted basouhils _ , 1 
using a QuickPrep Micro mRNA Purification Kit, and used as the 
template to synthesize the first strand cDNA with an oligo(dT)15 
primer and SUPERSCRIPT Reverse Transcriptase. Using the resultant 
first-strand cDNA as the template, the cDNA encoding the conserved 
PTP catalytic domain was amplified using AmpliTaq DNA polymerase 
in the presence of a pair of degenerate oligonucleotides, A and B, as 
the primer. After 25 cycles of amplification (94°C 1 min; SO”C, 1 min; 
72’C, 2 min) in a DNA Thermal Cycler (Cetus), the PCR product was 
cloned into the pCR II vector. 
2.5.2. PCR walking in the 5’ direction 
The first-strand cDNA template was synthesized using the total 
RNA isolated from basophil-enriched KU812E cells and sequence- 
specific oligonucleotide primers. The 5’ unknown regions were ampli- 
fied by our PCR walking method [lo]. 
2.5.3. Amplification of the 5’-end sequence of PTP-BAS 
The extreme 5’-end sequence of PTP-BAS cDNA was amplified by 
a combination of a modified 5’ RACE method and our two-step PCR 
[lo]. Briefly, a poly(dC) sequence was added to the 3’-end of the first- 
strand cDNA described in Section 2.5.2 using terminal deoxynucleoti- 
dvl transferase followina the 5’ RACE Svstem instructions. The second- 
strand cDNA was synthesized with an oligo(dG)l5 primer tagged with 
a unique sequence. Using the resultant double-stranded cDNA as the 
template, two-step PCR was performed using two pairs of nested prim- 
ers specific to unique tag and known BAS sequences as described [lo]. 
2.6. Isolation of PTP-BAS cDNA 
Total RNA was isolated from about 10’ basophil-enriched KU812E 
cells by the acid guanidium/phenol/chloroform ethod 1111, and 
poly(A)’ RNA was purified with a mRNA Purification Kit. From 3 pg 
of poly(A)’ RNA, a KU812E cell cDNA librarv was constructed using 
the SUPERSCRIPT Lambda System, the AZAP IUEcoRI Cloning Kz 
and Gigapack II Gold packaging extract. The resultant library con- 
tained 6.3 x lo5 independent recombinants. The PCR fragment of a 
novel PTP (named NPTP) was radiolabeled using [a-‘*PI dCTP and the 
Ready-To-Go DNA Labeling Kit. The KU812E cDNA library was 
screened with the radiolabeled NPTP probe at 60°C overnight in 
5 x SSC, 5 x Denhardt’s solution, 0.5% SDS containing salmon sperm 
DNA at lO,@ml. The filter was washed twice each with 2 x SSC, 0.1% 
SDS at room temperature for 10 min and with 1 x SSC, 0.1% SDS at 
42°C for 15 min. Selected clones were plaque-purified and underwent 
in vivo excision. 
2.7. Sequencing 
The cloned cDNA fragment was sequenced on an ALF DNA se- 
quencer (Pharmacia) using 5’-fluorescein-labelled oligonucleotide 
primers. The sequences cloned by PCR were finalized by sequencing at 
least three independently amplified clones. PCR fragments amplified in 
Sections 2.52 and 2.5.3 were directly sequenced with a dsDNA Cycle 
Sequencing System. Sequencing was done on both strands. 
2.8. Northern blot analysis 
Expression of PTP-BAS in various human tissues was examined 
using Multiple Tissue Northern Blots (Human MTN and Human Fetal 
MTN Blots). The BAS cDNA fragment (BAS-1, Fig. 1) and a human 
G3PDH control probe were radiolabeled using the Ready-To-Go DNA 
Labeling Kit. The blot was hybridized at 42°C for 16 h in 5 x SSPE, 
10 x Denhardt’s olution, 50% formamide, 2% SDS containing salmon 
sperm DNA at 100 @ml. The blot was washed twice with 2 x SSC, 
0.05% SDS at room temperature, twice with 1 x SSC, 0.1% SDS at 
50°C then twice with 0.1 x SSC, 0.1% SDS at 5O’C for 20 min each 
before exposure to a Kodak XAR-film at -80°C with an intensifying 
screen. 
3. Results 
3.1. Identzjication of a novel PTP 
To identify PTPs expressed in human basophils, se- 
quences in the PTP catalytic domain were amplified by 
PCR using the first-strand cDNA from FACS-sorted 
basophils as the template. A pair of degenerate primers 
(A and B) corresponding to the sequences that are highly 
conserved but which flank a region of variable sequences 
was used. The predicted PCR product was cloned into 
the pCR II vector and a total of 33 clones was sequenced. 
Among these, 27 were known PTPs, including LCA 
[12,13], MEG [14], MEG2 [15] and TCPTP [16]. The 
remaining six clones were identical and differed from the 
known PTPs. This PCR-amplified cDNA fragment was 
designated as NPTP (Figs. 1 and 2). 2.5 x lo5 recombi- 
nants out of a cDNA library from basophil-enriched 
KU812E cells was screened with the radiolabeled NPTP 
probe. Two positive clones were isolated and sequenced 
(BAS-1 in Figs. 1 and 2). Four consensus polyadenyla- 
tion signals (AATAAA) were found upstream from the 
poly (A) tail, but an in-frame stop codon preceding the 
initial methionine codon was not included, indicating 
that the coding region of BAS-1 extends further in the 
5’ direction. 
To synthesize the first-strand cDNA containing the 
most 5’ sequence of PTP-BAS, a sequence-specific oli- 
gonucleotide overlapping the S-end of BAS-1 was used 
as the primer. By using the resultant first-strand cDNA 
as the template, the 5’ unknown sequence was specifically 
amplified by our PCR walking method [lo]. Through six 
consecutive PCR walks, sequence of about 3 kilobases 
(kb) upstream from the S-end of BAS-1 was obtained. 
The S-end sequence of the PTP-BAS cDNA was ampli- 
fied by our improved S’RACE method (BAS-5 in Fig. 1) 
and overlapped with the sixth walking sequence. To ver- 
ify the sequence obtained by the S’PCR walking and 
S’RACE methods, overlapping cDNA fragments (BAS- 
2, -3 and -4 in Fig. 1) were amplified using sequence- 
specific primers, cloned into pCR II vectors and se- 
quenced. Two in-frame deletions were found in the BAS- 
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Fig. 1. The positions of the isolated BAS-1 and representative PCR fragments in the composite full-length PTP-BAS cDNA of three isoforms (types 
l-3). The scale indicates nucleotide positions beginning from the first base of the cDNAs. Deleted segments in types 2 and 3 are shown by nucleotide 
numbers in type 1. The coding region of PTP-BAS isoforms is described by boxes: solid, catalytic domain; hatched, membrane-binding domain; 
cross-hatched, GLGF repeats. Thin bars indicate the sizes and relative locations of each cDNA fragment sequenced in this study. 
Fig. 2. Nucleotide and deduced amino acid sequence of PTP-BAS (type 1). The numbers on the right and left are respectively for the nucleotide and 
amino acid sequences. Positions of in-frame deletions for type 2 (nucleotides 3,229-3,285) and type 3 (nucleotides 2,71333,285) are indicated by arrows. 
In-frame stop codons preceding and following the open reading frame are shown by asterisks. Consensus polyadenylation signals are boxed. The 
PCR product NPTP in the PTP catalytic domain is underlined. The 5’-end of the BAS-1 fragment is indicated by an inverted triangle. 
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BAS GQTKENRRKNRYKNILPYDATRVPLGDEGGYINASFIKIPVGKEEFVYIA~PLPTTVGD 2292 . . . . . . . . . . . 
Consensus i “’ NRY tiRi “’ Y NA ac i 
BAS F\MMI~QKSTVIANMTQEVEGEKIKC~IRYUIRNILGKTTMVSNRLRLALVRMX)LKGFVVRA 2354 
. . . :: ::: 
Consensus Ai i4 id V E KC YvlR 
BAS MTLEDlQTREVRHlSHLNFTAVIRDHDTPSOPDDLLTFlSYMRHlHRSGPllTHCSAGlGR 2414 
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Consensus R V#‘D P HCSAG GR 
BAS SGTLICIDVVLGLISQDLDFDISDLVRCMRLQRHGMVQTEWYIFCYQVILYVLTRLQA 2473 
Cmsensus b kk 6b 
Fig. 3. Sequence comparisons of the PTP catalytic domain in PTP-BAS and other known PTPs. The amino acid sequence of PTP-BAS (type 1) is 
numbered on the right. Consensus residues common to 12 representative PTPs (PTPlB [28], TCPTP [16], LAR [29], LCA [12,13], HPTPa, j$ y, 6, 
E and [ [9], DLAR [18], DPTP [18]) are shown [9]. Colons indicate identity with the consensus residues. 
2 fragments, suggesting that PTP-BAS exists in three 
isoforms (types 1, 2 and 3). 
The composite full-length nucleotide sequence desig- 
nated PTP-BAS type 1 contains a consensus initiation 
codon (AATATGC) [17] at position 64 and is preceded 
by an in-frame stop codon (Fig. 2). The initiation codon 
is followed by a single open reading frame of 7,455 bp 
encoding 2,485 amino acids. Types 2 and 3 lack respec- 
tively, nucleotides 3,229-3285 (amino acids 1,0561,074) 
and nucleotides 2,713-3,285 (amino acids 8841,074) in 
type 1 (Figs. 1 and 2). The open reading frames for types 
2 and 3 are 7,398 bp (2,466 residues) and 6,882 bp (2,294 
residues), respectively. All three isoforms of PTP-BAS 
contain a single PTP catalytic domain at their carboxyl 
termini (Figs. 1 and 2), where the cysteine (amino acid 
2,408 for type 1) essential to catalysis [18] and 98% of 42 
consensus residues common to 12 representative PTPs 
[9] are present (Fig. 3). 
3.2. Sequence similarities 
A homology search for the amino terminal region of 
the PTP catalytic domain was conducted using the Gen- 
Bank data base (release 78) with the FASTA program. 
Strong similarity (25-30% identity and 4650% similar- 
ity) was revealed between amino acids 574-881 of PTP- 
BAS and the amino terminal sequences of cytoskeleton- 
associated proteins (protein 4.1, ezrin, radixin and 
moesin of human and other species) and two cytosolic 
PTPs (PTPHl and PTP-MEG) (Figs. 4 and 6). Three 
GLGF repeats reported in the rat brain postsynaptic 
density protein (PSD-95) [19] as a homologue of the 
Drosophila lethal( l)discs-large-l tumor suppressor pro- 
tein (dls) [20] were found in the central part of PTP-BAS 
(amino acids 1,0941,178, 1,368-1,452 and 1,501-1,588 
for type 1) (Figs. 5 and 6). The repeats were 2344% 
identical and 43-63% similar (Fig. 5). 
3.3. Expression of PTP-BAS mRNA in the human tissues 
Northern blots showed that PTP-BAS was expressed 
in all human tissues examined (Fig. 7). After normaliza- 
tion of the signal obtained with a G3PDH probe, the 
levels of PTP-BAS expression in adult human tissues are 
BAS VNIMLLNGQRLELTCDTKTICKDVFDMVVAHIGLVEHHLFALATLKDNEYFFVDPDLKLTKVAPEGWKEEPKKKTKATV 
Ezrin VRVTTMDAE-LEFAIQPNTTGKQLFWVVKTIGLREVWYFGLHYVDNKGF---PTWLKLDKKVS---AQEVRKEN--PL 
Radixin VRVTTMDAE-LEFAIQPNTTGKQLFWVVKTVGLRE~FFGLQYVDSKGY---STWLKLNKKVT---QQDVKKEN--PL 
Mcesm VRVTTMDAE-LEFAIQPNTTGKQLFDQVVKTIGLREVWFFGLQYQDTKGF---SMILKLNKKVT---AQDVRKES--PL 
*. . . . . l *...* t..tt *t .*t l l .* . . *** l . . . .* . . 
BAS NFTLFFRIKFFMDDVSL-IQHTLTCHQYYLQLRKDILEERMHCDDETSLLLASLALQAEYGDYQPEVHGVSYFRMEHYL 
Ezr1Il QFK--FRAKFYPEDVAEELIQDlTQKLFFLQVKEGlLSDElYCPPETAVLLGSYAVQAKFGDYNKEVHKSGYLSSERLl 
Radlxln QFK-.FRAKFFPEDVSEELIQElTQRLFFLQVKEAlLNDElYCPPETAVLLASYAVQAKYGDYNKElHKPGYLANDRLL 
Moesin LFK--FRAKFYPEDVSEELIQDlTQRLFFLQVKEGlLNDDlYCPPETAVLLASYAVQSKYGDFNKEVHKSGYLAGDKLL 
+ l * **. .**. . .*. ..**.. **. . * +t..tt.* *.*. ,**.. t.* .* .* . 
BAS PARVMEKLDLSYIK--EELPKLHNTYVGASEKETELEFLKVCQRLTEYGVHFHRVHPEKKSQTGlLLGVCSKGVLVFEV 
Em PQRVMDQHKLTRWWEDRlQWVHAEHRGMLKDNAMLEYLKIAQDLEMYGINYFEIK--NKKGTDLWLGVDALGLNIYEK 
Radixin PQRVLEQHKLTKE~EERlQNWHEEHRGMLREDSMMEYLKIAQDLEMYGVNYFEIK--NKKGTELWLGVDALGLNIYEH 
Moesin PQRVLEQHKLNKWWEERlQVWHEEHRGMLREDAVLEYLKIAQDLEMYGVNYFSIK--NKKGSELWLGVDALGLNIYEQ 
* **.. * . . * * ., .*.**. * * **. , ,, * . . *** . l . ..* 
BAS HNGVRTLVLRFPWRETKKISFSKKKITLQNTSDGIKH-MRARQSNQDAQ 
Ezrin DDKLTPKI-GFPWSEIRNISFNDKKFVlKPlDKKAPDFVFYAPRLRlNKRlLQLCMGNHELYMRRRKPDTlEVQQ 
Radlxin DDKLTPKI-GFPWSEIRNISFNDKKFVIKPIDKKAPDFVFYAPRLRINKRILALCMGNHELYMRRRKPDTIEVQQ 
Moesin NDRLTPKI-GFPWSEIRNISFNDKKFVlKPlDKKAPDFVFYAPRLRlNKRlLALCMGNHELYMRRRKPDTlEVQQ 
. . . . l ** * . *** l * . * . .* .* l * .t . l . . . l 
Fig. 4. Alignment of amino acid sequences 574-881 of PTP-BAS with membrane-binding domains (amino acids 7-304) of the representative human 
cytoskeleton-associated proteins: ezrin [30], radixin [31] and moesin [32]. Identical amino acids are indicated by asterisks. Conserved amino acid 
changes are indicated by dots. 
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BAS 1501 
PSD-95 65 
PSD-95 160 
PSD-95 313 
df9 40 
dl9 154 
dig 466 
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db 
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Fig. 5. Alignment of three GLGF repeats of PTP-BAS, PSD-95 [19] and dlg [20]. Amino acid sequences of each repeat are numbered. More than 
three identical amino acids at one position are highlighted by a black box. Conserved amino acid changes are shadowed. 
as follows: the highest in the kidney; high in the lung; low 
in the placenta, brain, pancreas, heart and skeletal mus- 
cle; very low in the liver (Fig. 7A). Compared with the 
adult, the expression in human fetal (20-26 weeks) tis- 
sues was remarkably enhanced in the brain, but was 
similar in the kidney, lung, heart and liver (Fig. 7B). 
4. Discussion 
A novel PTP was identified from human basophils by 
PCR using degenerate primers deduced from conserved 
amino acid sequences in the PTP catalytic domain. A 
cDNA fragment of 4,663 bp (BAS-1 in Figs. 1 and 2) was 
cloned from a KU812E cDNA library. The 5’ unknown 
region was amplified and sequenced by our modified 5’ 
PCR walking and 5’ RACE methods. The composite 
full-length cDNA contains consensus polyadenylation 
signals with a poly(A) tail and a consensus initiation 
sequence of Kozak [17] preceded by an in-frame stop 
codon (Fig. 2). The coding region contains two distinct 
in-frame deletions, suggesting that three isoforms (types 
l-3) are expressed (Figs. 1 and 2). The estimated full- 
length cDNAs (8,139, 8,082 and 7,566 bp for types 1, 2 
and 3, respectively) correspond roughly to the size of the 
mRNA detected by Northern blotting (arrowed in Fig. 
7), although the size differences were too small to be 
distinguished in the corresponding bands. A single PTP 
catalytic domain is present at the carboxyl termini of all 
isoforms, that contains all but one of 42 conserved resi- 
dues in known PTPs [9] including the catalytically essen- 
tial cysteine residue [18] at 2,408 for type 1 (Fig. 3). This 
novel PTP is named PTP-BAS (after basophils). A hy- 
dropathy plot of the deduced amino acid sequences 
showed no hydrophobic regions that resemble a signal 
sequence or transmembrane domain (data not shown), 
and thus all isoforms of PTP-BAS are likely to be cyto- 
plasmic proteins. PTP-BAS is a cytosolic PTP of the 
largest molecule reported to date: 2,485 amino acid resi- 
dues for type 1, 2,466 residues for type 2 and 2,294 
residues for type 3 (Fig. 2). The existence in three 
isoforms may be of some functional importance. 
A homology search for the amino terminal region of 
the catalytic domain revealed that all isoforms contain 
two distinct structural sequences (Fig. 1). Amino acids 
571-881 of all the isoforms are highly similar to the 
amino terminal sequences of cytoskeleton-associated 
proteins: similar to the ezrin-radixin-moesin family [21] 
(27-29% identity and 50% similarity, Fig. 4) and some- 
what less similar to protein 4.1 [22] (25% identity and 
lr////717fl PTPHI 
p PTP-MEG 
m_ Moesin 
y//I-///fl Radixin 
B Ezrin 
y///7///1 Protein 4.1 
I v//,////1 IA-4 NVIFVU c1 BAS (type 1) 
..a PSD-95 . . . . 
KXY r:..::~ dig 
Fig. 6. A schematic diagram of structural domains of PTP-BAS (type 1) and its related proteins. PTP-BAS contains two distinct homologous domains: 
a membrane-binding domain (hatched bar) and three GLGF repeats (cross-hatched bar). Representative membrane-binding domains of human 
cytoskeleton-associated proteins (protein 4.1 [22], ezrin [30], radixin [31] and moesin [32]) and human cytosohc PTPs (PTP-MEG [14] and PTPHI 
[27]) are shown. Three GLGF repeats in cytoplasmic proteins (PSD-95 [19] and dlg [20]) are described. Other functional sequences shown in bars 
are PTP catalytic (solid) and guanylate kinase (stippled) domains, The length of each bar represents the actual length of the sequences. 
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(A) 
H B PQ Lu Li M K Pa 
G3PDH 
(B) 
H B Lu Li K 
Fig. 7. Detection of PTP-BAS mRNA from various human adult (A) 
and fetal (B) tissues using multiple tissue Northern blots (CLON- 
TECH). Each lane contains 2pg of poly(A)’ RNA. The blots were 
hybridized separately with the radiolabeled probes from BAS-1 and 
G3PDH cDNAs. PTP-BAS bands are marked by arrows. H, heart; B, 
brain; Pl, placenta; Lu, lung; Li, liver; M, skeletal muscle; K, kidney; 
Pa, pancreas. The numbers on the left are RNA sizes stated by the 
manufacturer. 
41% similarity). Protein 4.1 binds to the cytoplasmic end 
of transmembrane proteins glycophorin [23] and band 3 
[24] via the amino terminal domain [25]. Thus, the corre- 
sponding amino terminal region is called a membrane- 
binding domain [22]. Amino terminal domains of the 
ezrin-radixin-moesin family are homologous to the mem- 
brane-binding domain, so they are likely to bind to the 
plasma membrane [21,26]. The cytosolic PTPs contain- 
ing the membrane-binding domain reported so far are 
PTP-MEG [14] and PTPHl [27] (Fig. 6). PTP-BAS con- 
tains the other characteristic sequences: three 90 amino 
acid internal repeat sequences homologous to the GLGF 
repeats reported in guanylate kinase proteins: the rat 
brain PSD-95 protein [19] and the Drosophila dZg protein 
[20] (Figs. 5 and 6). These repeats are presumed to play 
a structural role in targeting the proteins to the submem- 
branous cytoskeleton or a functional role of regulating 
the enzyme activity [19]. PTP-BAS is thus a novel cy- 
tosolic PTP, supposedly attached to the plasma mem- 
brane via the amino terminal membrane-binding domain 
and its substrate-specificity or PTP activity is regulated 
via the central GLGF repeats. 
PTP-BAS initially cloned from human basophils was 
expressed in various human tissues, especially at the 
highest in the kidney and high in the lung. Interestingly, 
PTP-BAS was expressed at a remarkably high level in 
fetal, but weakly in the adult brain (Fig. 7). Furthermore, 
the PTP-BAS mRNA level increased with the growth 
and differentiation of human basophils cultured from 
cord blood mononuclear cells [lo] (data not shown). 
Thus, PTP-BAS may play a role in intracellular signal 
transduction and may be relevant to cell growth and 
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differentiation. The functional significance of this novel 
PTP is now under investigation. 
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